Bottom line
DLHCX vs ETHSX: the short answer
DLHCX (Nomura Healthcare Fund) and ETHSX (Eaton Vance Worldwide Health Sciences Fund) are both mutual funds.
But DLHCX is far broader, holding 108 positions to 42 for ETHSX, so beyond the top names it adds exposure ETHSX doesn't have.
ETHSX is cheaper at 1.18% vs 1.96% — a difference of $78 a year per $10,000 invested.
Over five years, DLHCX returned +6.7% a year vs +5.3% for ETHSX (reporting dates differ).
ETHSX has a front-end sales load of up to 5.25%; the other does not.
Updated Nov 19, 2026
DLHCX vs ETHSX side by side
| DLHCX | ETHSX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Voya | Morgan Stanley |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.96% | 1.18% |
| Annual cost per $10k | $196 | $118 |
| 10-yr cost on $10k (prospectus) | $2,334 | $1,911 |
| Max front load | 0% | 5.25% |
| 12b-1 fee | 1% | 0.25% |
| 1-yr return | +20.2% | −1.9% |
| 5-yr return (annualized) | +6.7% | +5.3% |
| 10-yr return (annualized) | +9.3% | +6.4% |
| Best quarter | — | +14.2% |
| Worst quarter | — | −12.1% |
| Net assets (fund) | $750.2M | $757.9M |
| Number of holdings | 108 | 42 |
| Portfolio turnover | 4% | 3% |
| Returns as of | Dec 31, 2025 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
10 of DLHCX's top 25 holdings also appear in ETHSX's top 25.
| Holding | DLHCX | ETHSX |
|---|---|---|
| Abbvie Inc | 4.19% | 6.46% |
| Eli Lilly & Company | 4.16% | 12.47% |
| Unitedhealth Group Inc | 3.88% | 5.49% |
| Merck & Company Inc | 3.68% | 5.08% |
| Gilead Sciences Inc | 3.54% | 3.34% |
| Astrazeneca Plc | 3.27% | 6.24% |
| Roche Holding Ag | 3.01% | 5.44% |
| Vertex Pharmaceuticals Inc | 1.66% | 3.38% |
| Neurocrine Biosciences Inc | 1.57% | 1.41% |
| Boston Scientific Corp | 1.42% | 2.18% |
Source: SEC Form N-PORT
DLHCX top 10
- Ucb Sa — 5.19%
- Abbvie Inc — 4.19%
- Eli Lilly & Company — 4.16%
- Regeneron Pharmaceuticals Inc — 3.91%
- Unitedhealth Group Inc — 3.88%
- Pfizer Inc — 3.84%
- Merck & Company Inc — 3.68%
- Gilead Sciences Inc — 3.54%
- Astrazeneca Plc — 3.27%
- Elevance Health Inc — 3.25%
ETHSX top 10
- Eli Lilly & Co — 12.47%
- AbbVie Inc — 6.46%
- Johnson & Johnson — 6.45%
- AstraZeneca PLC — 6.24%
- UnitedHealth Group Inc — 5.49%
- Roche Holding AG — 5.44%
- Merck & Co Inc — 5.08%
- Bristol-Myers Squibb Co — 4.25%
- Vertex Pharmaceuticals Inc — 3.38%
- Gilead Sciences Inc — 3.34%
FAQ
What is the difference between DLHCX and ETHSX?
Which is cheaper, DLHCX or ETHSX?
Should I own both DLHCX and ETHSX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.